In this study, we recruited 81 unmedicated patients with MDD and 123 demographically-matched healthy control subjects from the Mental Health Center of West China Hospital of Sichuan University that were matched for age and gender. Demographics of all subjects are shown in Table 1. All MDD patients were enrolled based on the Structured Clinical Interview for DSM-IV (SCID; First, 2002) for major depression, with Hamilton Depression Rating Scale (HDRS) score > 17 and age within 18–60 years. Exclusion criteria included patients with concurrent neurological illness, mental retardation, cardiovascular disease, bipolar disorder, schizophrenia, anxiety disorder, alcohol or drug abuse and history of loss of consciousness. To avoid the influence of medication, we ensured all patients enrolled in our study had stopped taking any antidepressants for at least 3 months before scanning (i.e. unmedicated MDD), while a subset of MDD patients (26/81, 32%) were previously treated with antidepressant medications. Detailed clinical information is presented in Table 1. All patients were assessed and scanned as soon as possible (usually within 3 days) to prevent treatment delay. Demographically, similar healthy volunteers were recruited by poster advertisements within the local community. The control subjects were also interviewed by professional psychiatrists using SCID non-patient edition (SCIDI/NP; APA, 2000) to ensure that none of them had a current or past history of depression, other major physical or neurological illnesses, or any substance abuse. All participants signed an informed consent form prior to participation in the study. This study was approved by the Ethics Committee of Sichuan University and conducted according to the Declaration of Helsinki. Tests from CANTAB (Robbins et al., 2010), imaging parameters and preprocessing details are presented in the Supplementary material.

Table 1

Demographic and clinical information

MDD (n = 81)HC (n = 123)t/χ2-tests
Demographic characteristics
Age, mean ± SD29 ± 19.827 ± 18.00.1
Gender, male/female28/5341/820.9
Education time, years, mean ± SD13.5 ± 2.914.6 ± 3.50.02
Clinical characteristics
HDRS, mean ± SD22.8 ± 4.1NANA
Total duration of illness, months, mean ± SD31.1 ± 48NANA
Current duration of illness, months, mean ± SD7.4 ± 12.8NANA
Presence of suicidal thoughts, yes/no40/41NANA
Presence of suicidal behaviour, yes/no7/74NANA
With/without family history6/75
Medical characteristics
No medication (68%)55123
Antidepressants (32%, taken at least 3 months ago)
    SSRIs (selective serotonin reuptake inhibitors)20NANA
    SNRIs (serotonin–norepinephrine reuptake inhibitors)3NANA
    NaSSAs (noradrenergic and specific serotonergic antidepressant)3NANA
MDD (n = 81)HC (n = 123)t/χ2-tests
Demographic characteristics
Age, mean ± SD29 ± 19.827 ± 18.00.1
Gender, male/female28/5341/820.9
Education time, years, mean ± SD13.5 ± 2.914.6 ± 3.50.02
Clinical characteristics
HDRS, mean ± SD22.8 ± 4.1NANA
Total duration of illness, months, mean ± SD31.1 ± 48NANA
Current duration of illness, months, mean ± SD7.4 ± 12.8NANA
Presence of suicidal thoughts, yes/no40/41NANA
Presence of suicidal behaviour, yes/no7/74NANA
With/without family history6/75
Medical characteristics
No medication (68%)55123
Antidepressants (32%, taken at least 3 months ago)
    SSRIs (selective serotonin reuptake inhibitors)20NANA
    SNRIs (serotonin–norepinephrine reuptake inhibitors)3NANA
    NaSSAs (noradrenergic and specific serotonergic antidepressant)3NANA

NA = not available.

Table 1

Demographic and clinical information

MDD (n = 81)HC (n = 123)t/χ2-tests
Demographic characteristics
Age, mean ± SD29 ± 19.827 ± 18.00.1
Gender, male/female28/5341/820.9
Education time, years, mean ± SD13.5 ± 2.914.6 ± 3.50.02
Clinical characteristics
HDRS, mean ± SD22.8 ± 4.1NANA
Total duration of illness, months, mean ± SD31.1 ± 48NANA
Current duration of illness, months, mean ± SD7.4 ± 12.8NANA
Presence of suicidal thoughts, yes/no40/41NANA
Presence of suicidal behaviour, yes/no7/74NANA
With/without family history6/75
Medical characteristics
No medication (68%)55123
Antidepressants (32%, taken at least 3 months ago)
    SSRIs (selective serotonin reuptake inhibitors)20NANA
    SNRIs (serotonin–norepinephrine reuptake inhibitors)3NANA
    NaSSAs (noradrenergic and specific serotonergic antidepressant)3NANA
MDD (n = 81)HC (n = 123)t/χ2-tests
Demographic characteristics
Age, mean ± SD29 ± 19.827 ± 18.00.1
Gender, male/female28/5341/820.9
Education time, years, mean ± SD13.5 ± 2.914.6 ± 3.50.02
Clinical characteristics
HDRS, mean ± SD22.8 ± 4.1NANA
Total duration of illness, months, mean ± SD31.1 ± 48NANA
Current duration of illness, months, mean ± SD7.4 ± 12.8NANA
Presence of suicidal thoughts, yes/no40/41NANA
Presence of suicidal behaviour, yes/no7/74NANA
With/without family history6/75
Medical characteristics
No medication (68%)55123
Antidepressants (32%, taken at least 3 months ago)
    SSRIs (selective serotonin reuptake inhibitors)20NANA
    SNRIs (serotonin–norepinephrine reuptake inhibitors)3NANA
    NaSSAs (noradrenergic and specific serotonergic antidepressant)3NANA

NA = not available.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close